{
    "clinical_study": {
        "@rank": "149543", 
        "arm_group": [
            {
                "arm_group_label": "1", 
                "arm_group_type": "Experimental", 
                "description": "Ticagrelor with Platelet transfusion"
            }, 
            {
                "arm_group_label": "2", 
                "arm_group_type": "Experimental", 
                "description": "Ticagrelor without Platelet transfusion"
            }, 
            {
                "arm_group_label": "3", 
                "arm_group_type": "Active Comparator", 
                "description": "Clopidogrel with Platelet transfusion"
            }, 
            {
                "arm_group_label": "4", 
                "arm_group_type": "Active Comparator", 
                "description": "Clopidogrel without Platelet transfusion"
            }
        ], 
        "brief_summary": {
            "textblock": "Study to see if platelet transfusion stop or lessen the effect of the drug on platelets"
        }, 
        "brief_title": "Study to See if Platelet Transfusion Stop or Lessen the Effect of the Drug on Platelets", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": "Inhibition on Platelet Aggregation", 
        "detailed_description": {
            "textblock": "A open label, randomized, crossover and potential parallel, single dose study of ticagrelor\n      180 mg and acetylsalicylic acid (ASA) in healthy volunteers followed by autologous in vivo\n      platelet transfusion to determine the effects of platelet supplementation on the\n      reversibility of platelet inhibition"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Provision of signed and dated, written informed consent prior to any study specific\n             procedures\n\n          -  Healthy male and/or female volunteers aged 18 to 50 years, inclusive, with suitable\n             veins for cannulation or repeated venipuncture. (Healthy as determined by medical\n             history and physical examination, laboratory parameters, electrocardiogram (ECG)\n             perform\n\n          -  Have a body mass index (BMI) between 18 and 35 kg/m2 (inclusive) and weigh at least\n             50 kg and no more than 120 kg\n\n        Exclusion Criteria:\n\n          -  ADP induced platelet aggregation <60% prior to platelet apheresis\n\n          -  History of peptic ulcer disease  Healthy volunteers with a propensity to bleed (eg,\n             due to recent trauma, recent surgery, active or recent gastrointestinal bleeding or\n             moderate hepatic impairment)\n\n          -  Any clinically significant illness, medical/surgical procedure or trauma within 4\n             weeks of the first administration of the investigational product\n\n          -  Current smokers, those who have smoked or used nicotine products within the previous\n             3 months and those who tested positive for cotinine at screening or at admission to\n             the study center"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "258", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01744288", 
            "org_study_id": "D5130C00079"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "1", 
                    "2"
                ], 
                "description": "Oral single loading dose 180ng", 
                "intervention_name": "Ticagrelor", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "3", 
                    "4"
                ], 
                "description": "Oral single loading dose 600mg", 
                "intervention_name": "Clopidogrel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "1", 
                    "2", 
                    "3", 
                    "4"
                ], 
                "description": "81mg once daily from day -2 up to platelet transfusion", 
                "intervention_name": "ASA", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Clopidogrel", 
                "Ticagrelor"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Phase 1 Safety ,", 
            "pharmacodynamic,", 
            "Ticagrelor,", 
            "Clopidogrel,", 
            "Platelets"
        ], 
        "lastchanged_date": "April 23, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Overland Park", 
                    "country": "United States", 
                    "state": "Kansas"
                }, 
                "name": "Research Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Open Label, Randomized, Crossover and Potential Parallel, Single Dose Study of Ticagrelor 180 mg and Acetylsalicylic Acid (ASA) in Healthy Volunteers Followed by Autologous in Vivo Platelet Transfusion to Determine the Effects of Platelet Supplementation on the Reversibility of Platelet Inhibition", 
        "overall_official": [
            {
                "affiliation": "AstraZeneca Wilmington US", 
                "last_name": "Glenn Carlson, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Overland Park US, Quintiles, Inc", 
                "last_name": "Phil Leese, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Wilmington, US AstraZeneca", 
                "last_name": "Judi Hsia, MD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Pharmacodynamics in terms of percent of inhibition of adenosine phosphatase (ADP)-induced platelet aggregation assessed by light transmission aggregometry (LTA) after loading dose of Ticagrelor", 
            "safety_issue": "No", 
            "time_frame": "Predose, 0h, 2h,6h,12h,24h,36h,48h,60h,72h,84h and 96h"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01744288"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacodynamics in  terms of platelet reactivity as measured by P2Y12 Reaction Units (PRU) using VerifyNow\u2122 after loading dose of Ticagrelor", 
                "safety_issue": "No", 
                "time_frame": "Predose, 0h, 2h,6h,12h,24h,36h,48h,60h,72h,84h and 96h"
            }, 
            {
                "measure": "Pharmacodynamics in  terms of platelet reactivity as measured by P2Y12 Reaction Units (PRU) using VerifyNow\u2122 after loading dose of  Clopidogrel", 
                "safety_issue": "No", 
                "time_frame": "Predose, 0h, 2h,6h,12h,24h,36h,48h,60h,72h,84h and 96h"
            }, 
            {
                "measure": "Pharmacodynamics in terms of percent of inhibition of adenosine phosphatase (ADP)-induced platelet aggregation assessed by light transmission aggregometry (LTA) after loading dose of Clopidogrel", 
                "safety_issue": "No", 
                "time_frame": "Predose, 0h, 2h,6h,12h,24h,36h,48h,60h,72h,84h and 96h"
            }, 
            {
                "measure": "Safety profile in terms of adverse events, blood pressure, pulse, temperature, ECG (Electrocardiogram),  physical examination, and safety laboratory variables", 
                "safety_issue": "Yes", 
                "time_frame": "up to 9 weeks"
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}